|
1
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al
AURA3 Investigators: Osimertinib or Platinum-Pemetrexed in EGFR
T790M-Positive Lung Cancer. N Engl J Med. 376:629–640. 2017.
View Article : Google Scholar
|
|
8
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
9
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS,
Teng D and Lee KD: Overall survival benefits of first-line EGFR
tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung
cancers: A systematic review and meta-analysis. Br J Cancer.
113:1519–1528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al FLAURA Investigators: Osimertinib in
Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl
J Med. 378:113–125. 2018. View Article : Google Scholar
|
|
12
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tong JH, Yeung SF, Chan AW, Chung LY, Chau
SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, et al: MET
Amplification and Exon 14 Splice Site Mutation Define Unique
Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor
Prognosis. Clin Cancer Res. 22:3048–3056. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yano S, Yamada T, Takeuchi S, Tachibana K,
Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et
al: Hepatocyte growth factor expression in EGFR mutant lung cancer
with intrinsic and acquired resistance to tyrosine kinase
inhibitors in a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marcoux N, Gettinger SN, O'Kane G, Arbour
KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi
PD, et al: EGFR-Mutant Adenocarcinomas That Transform to Small-Cell
Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
J Clin Oncol. 37:278–285. 2019. View Article : Google Scholar
|
|
17
|
Suda K, Tomizawa K, Fujii M, Murakami H,
Osada H, Maehara Y, Yatabe Y, Sekido Y and Mitsudomi T: Epithelial
to mesenchymal transition in an epidermal growth factor
receptor-mutant lung cancer cell line with acquired resistance to
erlotinib. J Thorac Oncol. 6:1152–1161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC,
Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al:
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per
se is a common mechanism for acquired resistance to EGFR TKI.
Oncogene. 38:455–468. 2019. View Article : Google Scholar
|
|
19
|
Chung JH, Rho JK, Xu X, Lee JS, Yoon HI,
Lee CT, Choi YJ, Kim HR, Kim CH and Lee JC: Clinical and molecular
evidences of epithelial to mesenchymal transition in acquired
resistance to EGFR-TKIs. Lung Cancer. 73:176–182. 2011. View Article : Google Scholar
|
|
20
|
Li L, Gu X, Yue J, Zhao Q, Lv D, Chen H
and Xu L: Acquisition of EGFR TKI resistance and EMT phenotype is
linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.
Oncotarget. 8:92240–92253. 2017.PubMed/NCBI
|
|
21
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-β IL-6 axis mediates selective and adaptive mechanisms
of resistance to molecular targeted therapy in lung cancer. Proc
Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar
|
|
22
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuramochi-Miyagawa S, Watanabe T, Gotoh K,
Takamatsu K, Chuma S, Kojima-Kita K, Shiromoto Y, Asada N, Toyoda
A, Fujiyama A, et al: MVH in piRNA processing and gene silencing of
retrotransposons. Genes Dev. 24:887–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Santosh B, Varshney A and Yadava PK:
Non-coding RNAs: Biological functions and applications. Cell
Biochem Funct. 33:14–22. 2015. View Article : Google Scholar
|
|
27
|
Schmitt AM and Chang HY: Long Noncoding
RNAs in Cancer Pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yarmishyn AA and Kurochkin IV: Long
noncoding RNAs: A potential novel class of cancer biomarkers. Front
Genet. 6:1452015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tao H, Yang JJ, Zhou X, Deng ZY, Shi KH
and Li J: Emerging role of long noncoding RNAs in lung cancer:
Current status and future prospects. Respir Med. 110:12–19. 2016.
View Article : Google Scholar
|
|
30
|
Wang Q, Cheng N, Li X, Pan H, Li C, Ren S,
Su C, Cai W, Zhao C, Zhang L, et al: Correlation of long non-coding
RNA H19 expression with cisplatin-resistance and clinical outcome
in lung adenocarcinoma. Oncotarget. 8:2558–2567. 2017.
|
|
31
|
Wang B, Jiang H, Wang L, Chen X, Wu K,
Zhang S, Ma S and Xia B: Increased MIR31HG lncRNA expression
increases gefitinib resistance in non-small cell lung cancer cell
lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett.
13:3494–3500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan
H, Zhao M, Li J, Zhang Y, Zhao C, et al: Long non-coding RNA UCA1
induces non-T790M acquired resistance to EGFR-TKIs by activating
the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Oncotarget. 6:23582–23593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen LL: Linking Long Noncoding RNA
Localization and Function. Trends Biochem Sci. 41:761–772. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar
|
|
35
|
Goff LA and Rinn JL: Linking RNA biology
to lncRNAs. Genome Res. 25:1456–1465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang KC, Yang YW, Liu B, Sanyal A,
Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta
RA, et al: A long noncoding RNA maintains active chromatin to
coordinate homeotic gene expression. Nature. 472:120–124. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Flynn RA and Chang HY: Long noncoding RNAs
in cell-fate programming and reprogramming. Cell Stem Cell.
14:752–761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pandey RR, Mondal T, Mohammad F, Enroth S,
Redrup L, Komorowski J, Nagano T, Mancini-Dinardo D and Kanduri C:
Kcnq1ot1 antisense noncoding RNA mediates lineage-specific
transcriptional silencing through chromatin-level regulation. Mol
Cell. 32:232–246. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang L, Froberg JE and Lee JT: Long
noncoding RNAs: Fresh perspectives into the RNA world. Trends
Biochem Sci. 39:35–43. 2014. View Article : Google Scholar :
|
|
40
|
Good MC, Zalatan JG and Lim WA: Scaffold
proteins: Hubs for controlling the flow of cellular information.
Science. 332:680–686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hung T and Chang HY: Long noncoding RNA in
genome regulation: Prospects and mechanisms. RNA Biol. 7:582–585.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kallen AN, Zhou XB, Xu J, Qiao C, Ma J,
Yan L, Lu L, Liu C, Yi JS, Zhang H, et al: The imprinted H19 lncRNA
antagonizes let-7 microRNAs. Mol Cell. 52:101–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X,
Lin L, Yao H, Su F, Li D, et al: A cytoplasmic NF-κB interacting
long noncoding RNA blocks IκB phosphorylation and suppresses breast
cancer metastasis. Cancer Cell. 27:370–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu J, Lichtenberg T, Hoadley KA, et al:
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive
High-Quality Survival Outcome Analytics. Cell. 173:400–416.e411.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Livak KJ and Schmittgen TD: Analysis of
Relative Gene Expression Data Using Real-Time Quantitative PCR and
the 2(-Delta Delta C(T)). Method Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
48
|
Ran FA, Hsu PD, Wright J, Agarwala V,
Scott DA and Zhang F: Genome engineering using the CRISPR-Cas9
system. Nat Protoc. 8:2281–2308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aparicio-Prat E, Arnan C, Sala I, Bosch N,
Guigó R and Johnson R: DECKO: Single-oligo, dual-CRISPR deletion of
genomic elements including long non-coding RNAs. BMC Genomics.
16:8462015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen YR, Fu YN, Lin CH, Yang ST, Hu SF,
Chen YT, Tsai SF and Huang SF: Distinctive activation patterns in
constitutively active and gefitinib-sensitive EGFR mutants.
Oncogene. 25:1205–1215. 2006. View Article : Google Scholar
|
|
51
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kong YG, Cui M, Chen SM, Xu Y, Xu Y and
Tao ZZ: LncRNA-LINC00460 facilitates nasopharyngeal carcinoma
tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene.
639:77–84. 2018. View Article : Google Scholar
|
|
53
|
Li K, Sun D, Gou Q, Ke X, Gong Y, Zuo Y,
Zhou JK, Guo C, Xia Z, Liu L, et al: Long non-coding RNA linc00460
promotes epithelial-mesenchymal transition and cell migration in
lung cancer cells. Cancer Lett. 420:80–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J,
Shi Y, Ren J, Ji G and Wang K: A Novel lncRNA, LINC00460, Affects
Cell Proliferation and Apoptosis by Regulating KLF2 and CUL4A
Expression in Colorectal Cancer. Mol Ther Nucleic Acids.
12:684–697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu X, Wen J, Wang H and Wang Y: Long
non-coding RNA LINC00460 promotes epithelial ovarian cancer
progression by regulating microRNA-338-3p. Biomed Pharmacother.
108:1022–1028. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li P, Shan JX, Chen XH, Zhang D, Su LP,
Huang XY, Yu BQ, Zhi QM, Li CL, Wang YQ, et al: Epigenetic
silencing of microRNA-149 in cancer-associated fibroblasts mediates
prostaglandin E2/interleukin-6 signaling in the tumor
microenvironment. Cell Res. 25:588–603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Matsumoto A, Pasut A, Matsumoto M,
Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI,
Clohessy JG and Pandolfi PP: mTORC1 and muscle regeneration are
regulated by the LINC00961-encoded SPAR polypeptide. Nature.
541:228–232. 2017. View Article : Google Scholar
|
|
61
|
Tamura T, Kato Y, Ohashi K, Ninomiya K,
Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, et
al: Potential influence of interleukin-6 on the therapeutic effect
of gefitinib in patients with advanced non-small cell lung cancer
harbouring EGFR mutations. Biochem Biophys Res Commun. 495:360–367.
2018. View Article : Google Scholar
|
|
62
|
Matsui M and Corey DR: Non-coding RNAs as
drug targets. Nat Rev Drug Discov. 16:167–179. 2017. View Article : Google Scholar
|
|
63
|
Setten RL, Rossi JJ and Han SP: The
current state and future directions of RNAi-based therapeutics. Nat
Rev Drug Discov. 18:421–446. 2019. View Article : Google Scholar : PubMed/NCBI
|
